RecallRadar

FDA Drug recall D-0349-2019

Aprepitant Capsules, USP 40 mg, 1 capsule Unit Blister Pack, Rx Only, Manufactured in India for: Glenmark Pharmaceuticals Inc., USA Mahwah,…

On 2018-12-26 the FDA classified a Class III recall of Aprepitant Capsules, USP 40 mg, 1 capsule Unit Blister Pack, Rx Only, Manufactured in India for: Glenmark Pharmaceuticals Inc., USA Mahwah,… by Glenmark Pharmaceuticals Usa, citing shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0349-2019
ClassificationClass III
Statusterminated
Initiated2018-11-27
Published2018-12-26
Last updated2026-09-13 11:52 UTC
CompanyGlenmark Pharmaceuticals Usa
DistributionUS

Product

Aprepitant Capsules, USP 40 mg, 1 capsule Unit Blister Pack, Rx Only, Manufactured in India for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430. UPC 368462583401. NDC 68462-583-40

Reason

Shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.

Identifiers

upc368462583401
ndc68462-583-11
ndc68462-583-85
ndc68462-583-40
ndc68462-584-58
ndc68462-584-40
ndc68462-584-76
ndc68462-585-40
ndc68462-585-76
ndc68462-112-33
ndc3684625834
code_infoLot: 17180918, EXP June 2020

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0349-2019%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.